{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:45:08Z","timestamp":1788230708728,"version":"build-2803163510"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Ethical, administrative, regulatory, and logistical (EARL) procedures can hamper clinical trial delivery. Quantification of these hurdles is rare, prohibiting identification of areas for improvement.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify and quantify EARL hurdles in trial delivery before and during the COVID-19 pandemic.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used data from the ongoing Randomized Embedded Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia to enable comparison of EARL procedures for multiple protocols across 19 European countries in the pre\u2013COVID-19 pandemic (February 19, 2016 to March 10, 2020) and COVID-19 pandemic (March 11, 2020, to May 4, 2023) periods. Data were analyzed from November 2024 to March 2025 with contracts and protocol submissions as the units of analysis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Time to (1) site contract completion, (2) regulatory and ethical approval (TTA), and (3) first patient in (FPI). The UK was compared with non-UK countries because of its distinct research infrastructure.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were 257 fully signed first contracts with study sites for analysis. In the UK, contract completion times decreased by 97% (95% CI, 95% to 98%), from a median (IQR) of 196 (154 to 250) days in the pre\u2013COVID-19 pandemic period to 5 (1 to 11) days during the COVID-19 pandemic. In non-UK countries, median (IQR) contract completion times were 224 (119 to 412) days and 183 (62 to 291) days before and during the COVID-19 pandemic, respectively (relative difference, \u221218%; 95% CI, \u221243% to 52%). In total, 44 interventions in 16 domains were submitted, yielding 232 protocol approvals for analysis. During the COVID-19 pandemic, median (IQR) TTA was 8 (5 to 31) days in the UK and 115 (47 to 103) days in non-UK countries (median difference, 107 days; 95% CI, 76 to 123 days), with large variation across non-UK countries. Time between approval and FPI during the COVID-19 pandemic was, on average, 3 months faster in the UK compared with non-UK countries (median difference, 90 days; 95% CI, 42 to 141 days).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This study found that EARL procedures were lengthy and variable between countries, reflecting different interpretations of trial regulations, with faster processes in the UK. These findings underscore the need to streamline processes across European countries to improve trial efficiency, in particular during future public health emergencies such as pandemics.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.18503","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:00:25Z","timestamp":1751454025000},"page":"e2518503","source":"Crossref","is-referenced-by-count":9,"title":["Hurdles for the Delivery of Multinational Randomized Clinical Trials"],"prefix":"10.1001","volume":"8","author":[{"given":"Denise","family":"van Hout","sequence":"first","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mouncey","sequence":"additional","affiliation":[{"name":"Intensive Care National Audit and Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harrison","sequence":"additional","affiliation":[{"name":"Intensive Care National Audit and Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bonten","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands"},{"name":"European Clinical Research Alliance on Infectious Diseases, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennie","family":"Derde","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands"},{"name":"Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"REMAP-CAP European Regional Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek C.","family":"Angus","sequence":"additional","affiliation":[{"name":"Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Anjum","sequence":"additional","affiliation":[{"name":"Division of Anaesthetics, Pain Medicine, and Intensive Care, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djillali","family":"Annane","sequence":"additional","affiliation":[{"name":"Prometheus University Hospital Institute Sepsis Comprehensive Center, Raymond Poincar\u00e9, Hospital Assistance Publique-H\u00f4pitaux de Paris, University of Paris Saclay, Garches, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Best-Lane","sequence":"additional","affiliation":[{"name":"Division of Anaesthetics, Pain Medicine, and Intensive Care, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Brunkhorst","sequence":"additional","affiliation":[{"name":"Center for Sepsis Control and Care, Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cecconi","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Units, Istituto di Ricerca e Cura a Carattere Scientifico, Humanitas Research Hospital, Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ehrmann","sequence":"additional","affiliation":[{"name":"Centre d\u2019\u00c9tude des Pathologies Respiratoires, INSERM U1100, Tours, France"},{"name":"M\u00e9decine Intensive R\u00e9animation, INSERM CIC 1415, Critical Infections, Sepsis and Severe Disease Network, French Clinical Research Infrastructure Network, Centre Hospitalier R\u00e9gional Universitaire de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Anaesthetics, Pain Medicine, and Intensive Care, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne Marie","family":"Hays","sequence":"additional","affiliation":[{"name":"University College Dublin-Clinical Research Centre, St Vincents University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmee","family":"Kester","sequence":"additional","affiliation":[{"name":"European Clinical Research Alliance on Infectious Diseases (Ecraid), Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Mahon","sequence":"additional","affiliation":[{"name":"University College Dublin-Clinical Research Centre, St Vincents University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"McArthur","sequence":"additional","affiliation":[{"name":"Auckland City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Nichol","sequence":"additional","affiliation":[{"name":"University College Dublin-Clinical Research Centre, St Vincents University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Peters","sequence":"additional","affiliation":[{"name":"European Clinical Research Alliance on Infectious Diseases (Ecraid), Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Units, Istituto di Ricerca e Cura a Carattere Scientifico, Humanitas Research Hospital, Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Rowan","sequence":"additional","affiliation":[{"name":"Intensive Care National Audit and Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Torre-Cisneros","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Reina Sofia University Hospital, Instituto Maimonides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, University of C\u00f3rdoba, CIBERINFEC, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Weis","sequence":"additional","affiliation":[{"name":"Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany"},{"name":"Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany"},{"name":"Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"2","key":"zoi250579r1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jama.2024.4088","article-title":"The integration of clinical trials with the practice of medicine: repairing a house divided.","volume":"332","author":"Angus","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"zoi250579r3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1513\/AnnalsATS.202003-192SD","article-title":"The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study: rationale and design.","volume":"17","author":"Angus","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"7624","key":"zoi250579r4","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"16","key":"zoi250579r9","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19.","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi250579r10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial.","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"zoi250579r11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00134-021-06448-5","article-title":"Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.","volume":"47","author":"Arabi","year":"2021","journal-title":"Intensive Care Med"},{"issue":"7","key":"zoi250579r12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00134-023-07095-8","article-title":"Continuation of therapeutic dose heparin for critically ill patients with COVID-19.","volume":"49","author":"Bradbury","year":"2023","journal-title":"Intensive Care Med"},{"issue":"13","key":"zoi250579r13","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.2022.2910","article-title":"Effect of antiplatelet therapy on survival and organ support\u2013free days in critically ill patients with COVID-19: A randomized clinical trial.","volume":"327","author":"Bradbury","year":"2022","journal-title":"JAMA"},{"issue":"14","key":"zoi250579r14","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jama.2023.4480","article-title":"Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19: A randomized clinical trial.","volume":"329","author":"Lawler","year":"2023","journal-title":"JAMA"},{"issue":"25","key":"zoi250579r15","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1056\/NEJMoa2309995","article-title":"Simvastatin in critically ill patients with covid-19.","volume":"389","author":"Hills","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi250579r16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with covid-19.","volume":"385","author":"Goligher","year":"2021","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi250579r17","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support\u2013free days in critically ill patients with COVID-19: a randomized clinical trial.","volume":"326","author":"Estcourt","year":"2021","journal-title":"JAMA"},{"issue":"18","key":"zoi250579r18","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1001\/jama.2023.21407","article-title":"Intravenous vitamin C for patients hospitalized with COVID-19: two harmonized randomized clinical trials.","volume":"330","author":"Adhikari","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"zoi250579r19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.accpm.2020.06.010","article-title":"COVID-19 studies registration worldwide for prospective studies with a specific focus on the fast-tracking of French ethic procedures.","volume":"39","author":"Gremi","year":"2020","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"1","key":"zoi250579r20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13063-023-07869-x","article-title":"Experiences and challenges with the new European clinical trials regulation.","volume":"25","author":"Patrick-Brown","year":"2024","journal-title":"Trials"},{"issue":"19","key":"zoi250579r22","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1001\/jama.2020.4984","article-title":"Optimizing the trade-off between learning and doing in a pandemic.","volume":"323","author":"Angus","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"zoi250579r23","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/v14071427","article-title":"Pharmacological studies in hospitalized COVID-19 patients in Belgium: we could do better.","volume":"14","author":"Hites","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"zoi250579r24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cmi.2021.10.011","article-title":"Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group.","volume":"28","author":"Diallo","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"zoi250579r25","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jama.2021.3284","article-title":"Emerging lessons from COVID-19 for the US clinical research enterprise.","volume":"325","author":"Angus","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"zoi250579r26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jama.2024.0269","article-title":"Making the ethical oversight of all clinical trials fit for purpose.","volume":"333","author":"Kass","year":"2024","journal-title":"JAMA"},{"key":"zoi250579r2","unstructured":"National Health Service. Novel coronavirus: clinical trials. Published April 1, 2020. Accessed 6 December, 2024. https:\/\/www.cas.mhra.gov.uk\/ViewandAcknowledgment\/ViewAlert.aspx?AlertID=103012"},{"key":"zoi250579r5","unstructured":"World Health Organization. Statement on the fifteenth meeting of the IHR (2005) emergency committee regarding the COVID-19 pandemic. Published May 5, 2023. Accessed May 28, 2025. https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic"},{"key":"zoi250579r6","unstructured":"European Union. Directive 2001\/20\/EC o the European parliament and of the council on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Union. Published April 4, 2001. Accessed May 28, 2025. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32001L0020."},{"key":"zoi250579r7","unstructured":"European Union. Directive 2005\/28\/EC laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products. Official Journal of the European Union. Published April 8, 2005. Accessed May 28, 2025. https:\/\/eur-lex.europa.eu\/eli\/dir\/2005\/28\/oj\/eng"},{"key":"zoi250579r8","unstructured":"European Union. Regulation (EU) No 536\/2014 of the European parliament and of the council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing directive 2001\/20\/EC. Published April 16, 2024. Accessed May 28, 2025. https:\/\/eur-lex.europa.eu\/eli\/reg\/2014\/536\/oj\/eng"},{"key":"zoi250579r21","unstructured":"National Health Service Health Research Authority. Examples of substantial and non-substantial amendments. Updated March 25, 2021. Accessed December 9, 2024. https:\/\/www.hra.nhs.uk\/approvals-amendments\/amending-approval\/examples-of-substantial-and-non-substantial-amendments\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835887\/van_hout_2025_oi_250579_1784059932.90219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:01:10Z","timestamp":1784214070000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.18503","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}